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Aims: This study aimed to assess the inﬂuence of pharmacotherapy on health-related qual-
ity  of life of elderly with ostheoarthritis.
Methods: Longitudinal study involving 91 older adults from both genders (Age: 70.36 ± 5.57
years) from EELO project with self-reported knee or hip ostheoartritis, conﬁrmed by
radiographic analysis. Data regarding pharmacotherapy was assessed by a structured ques-
tionnaire and the quality of life was analyzed by SF-36 questionnaire at the initial moment
and  two years thereafter. All domains from quality of life were grouped in physical and
mental components for further data analysis.
Results: A statistically signiﬁcant decline in both physical and mental components of quality
of  life was  observed (Wilcoxon test, p < 0.05). However, it was observed a slighted decline in
physical components in group treated with chondroitin/glucosamine when compared to
other groups, according to Kruskal–Wallis test (p = 0.007). On the other hand, it was not
observed any inﬂuence of pharmacological treatment on mental components of health-
related quality of life (p > 0.05).
Conclusions: Treatment with condroitin/glucosamin contributes to a lower decline in physi-
cal  component while it had no inﬂuence on mental component of health-related quality ofith ostheoartritis.life in older adults w
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Análise  da  inﬂuência  da  farmacoterapia  sobre  a  qualidade  de  vida  em
idosos  com  osteoartrite
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Objetivos: Analisar a inﬂuência da farmacoterapia da osteoartrite na qualidade de vida de
idosos.
Métodos: Estudo longitudinal, do qual participaram 91 idosos de ambos os gêneros (idade:
70,36  ± 5,57 anos), integrantes do projeto Estudo sobre Envelhecimento e Longevidade
(EELO), portadores de osteoartrite de quadril e/ou joelho, conﬁrmada por análise radiográ-
ﬁca. Foram levantados dados sobre a farmacoterapia da osteoartrite mediante o uso de
questionários estruturados e a qualidade de vida foi analisada pelo questionário SF-36, no
momento inicial e dois anos após a coleta de dados. Os diferentes domínios da qualidade
de  vida foram agrupados em domínios físicos e mentais para posterior análise dos dados.
Resultados: Foi observado um declínio estatisticamente signiﬁcativo tanto nos componentes
físicos quanto mentais da qualidade de vida dos indivíduos (teste de Wilcoxon, p < 0,05). Foi
observado menor declínio no componente físico da qualidade de vida para os usuários de
condroitina/glicosamina em comparac¸ão com o grupo tratado com anti-inﬂamatórios ou
não  tratado, segundo o teste de Kruskal–Wallis (p = 0,007). Por outro lado, não foi observada
inﬂuência do tratamento farmacológico sobre o componente mental da qualidade de vida
(p  > 0,05).
Conclusão: O tratamento com condroitina/glicosamina contribuiu para menor declínio do
componente físico e não inﬂuenciou os componentes mentais da qualidade de vida de
idosos com osteoartrite.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
Osteoarthritis (OA), also known as arthrosis and osteoarthro-
sis, is a chronic degenerative disease caused by the
deterioration of the cartilage and the formation of marginal
osteophyte, with bone outgrowths on the surfaces and at the
margins of the joints.1 It is characterized by pain and func-
tional limitations, it has slow evolution, as a result of the
imbalance between the formation and elimination of the main
elements of the cartilage.2
OA is age-related,1 being the rheumatic disorder more
prevalent among the elderly,3 affecting approximately 10% of
the world’s elderly population.4 Despite there is no accurate
data in Brazil, Backer study5 shows prevalence of 26.3%. In this
context, it represents one of the most frequent causes of dis-
ability and pain in the musculoskeletal system.3 Knee OA is
the most common manifestation, affecting 23% of the elderly
population, although these numbers are even higher among
elderly women.6 However, the prevalence of OA can reach 40%
among individuals aged 74 or older.6
The cartilage lesion may be caused by a mechanical aggres-
sion or due to inﬂammatory joint disease, and it has strong
genetic predisposition.1,2
Its pathophysiology is characterized by severe changes
in the joint surface (loss of articular cartilage, ulceration,
remodeling and sclerosis of the subchondral bone), with sud-
den biochemical changes in the proteoglycans, resulting in
catabolic and anabolic processes in the cartilage metabolism,
with reduced levels of chondroitin and glucosamine sulfates.1Its symptoms are basically constant: localized articular
pain, which accentuates with increasing load and move-
ment (worse at the beginning of the movement  and at rest),
reduced range of motion, muscle weakness, joint stiffness
after rest, crepitus and increased articular volume, with conse-
quent progressive inability to perform usual activities, such as
gait.1
OA is initially treated with physical measures, analgesics,
steroidal and nonsteroidal anti-inﬂammatories (NSAIDs), and
surgical treatment is indicated for the most severe cases
only. However, based on the actual knowledge of the disease
pathophysiology, disease modifying drugs, such as chon-
droitin and glucosamine seems to be able to abolish or
reduce its symptoms, increasing functional status of the
patients.2,7
Quality of life is an important item in the health of the
individual that should be considered in the study of OA.8
According to the World Health Organization (WHO), quality
of life is the individual’s perception of their position in life,
in the context of culture and in the value systems in which
they live and in relation to their goals, their expectations,
their standards and concerns.9 The instruments that assess
quality of life may be inﬂuenced by the impact of the health
condition in life, including the physical, emotional and social
domains.10
Considering the concern over the use of medications in
elderly patients with OA, the aim of this study was to analyze
the effect of pharmacotherapy on the quality of life of these
individuals.
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of life when compared to the group being treated with anti-
inﬂammatories, or untreated, according to the Kruskal–Wallisr e v b r a s r e u m a t
atients  and  methods
thical  procedures
his study was approved by the Research Ethics Committee
protocol no. 0063/09). Before any procedure was undertaken,
atients were briefed on the nature of the work and signed
 free and informed consent form in which they agreed to
articipate in the study.
utline  and  study  population
inety-one elderly patients with OA from a subsample of EELO
roject were included in this longitudinal, observational study.
EELO was a thematic project developed in the city of
ondrina, Paraná, which aimed to examine the social and
emographic conditions and health indicators of elderly indi-
iduals of this city. The project had a total sample of 508
eniors, who were selected in a random and stratiﬁed manner
rom the records of Basic Health Units from this city.
The criteria for inclusion were patients of both genders,
ged 60 years or older and diagnosis of hip and knee OA, either
eceiving clinically prescribed drug treatment or not and who
ad signed a free and informed consent.
The criteria for exclusion were individuals with full or
artial prosthetics in any of the joints being evaluated, with
oncomitant diagnosis of other osteoarticular/muscle dis-
ases, such as rheumatoid arthritis, ﬁbromyalgia, systemic
upus erythematosus and other rheumatic diseases with
evere cognitive impairment or those who have not agreed
o sign the free and informed consent form.
nstrumentation
 structured interview guide with questions about gender, age,
eight, height, race, previous occupation and occupational
tatus was used to characterize the proﬁle of senior patients
ith OA. The formula: weight (kg)/height2 (m2) was used to
alculate the body mass index (BMI).
A structured questionnaire with information about drug
ype, dosage and duration of the treatment of patients with OA
as used to evaluate the drug treatment adopted by the indi-
iduals. Then the patients were divided into three subgroups
ccording to the treatment, for further statistical comparison:
ontrol group (individuals who  are not making use of med-
cation for OA), anti-inﬂammatory group (individuals being
reated with steroidal anti-inﬂammatories and NSAIDs) or
he chondroitin/glucosamine group (individuals being treated
ith the chondroitin + glucosamine association).
The Medical Outcomes Study 36 Short-Form Health
urvey (SF-36) questionnaire, translated and validated into
ortuguese and currently recommended by the American Col-
ege of Rheumatology, was used to assess the quality of life.
he SF-36 questionnaire is an instrument that covers the fol-
owing domains: functional capacity, physical aspects, bodily
ain, general health condition, vitality, social aspects, emo-
ional aspects and mental health.
The ﬁrst four domains (functional capacity, physical
spects, bodily pain, general health condition) assess the 0 1 5;5  5(1):83–88 85
physical health or physical component, while the last four
(vitality, social aspects, emotional aspects and mental health),
the mental health or mental component. The score of each
domain varies from zero to 100, in which zero corresponds to
the worst health condition and 100, to the best. Each domain
is analyzed separately, and there is no overall score.11
Procedures
Data collection procedures were carried out in two stages.
With the objective of evaluating the variation in the quality
of life of these elderly patients over time and with pharma-
cotherapy, these were reevaluated two years after the initial
collection, i.e., the ﬁrst evaluation was made in 2010 and the
second in 2012.
Statistical  analysis
A database was prepared in the Statistical Package for Social
Sciences (SPSS) program, version 15.0, from the data collected.
A conﬁdence interval (CI) of 95% was established for all tests
applied (p < 0.05).
Initially, the Shapiro–Wilk normality test was used and,
as the data did not display a normal distribution, descrip-
tive data, such as median and interquartile range (median;
Q1–Q3) and nonparametric tests were applied to compare the
groups.
The Wilcoxon test was used to compare the difference in
the physical and mental components of the life quality of
each group between evaluations (initial evaluation and ﬁnal
evaluation, carried out two years after the initial analysis).
In order to analyze if any pharmacological treatment would
be related to a smaller decline of functional capacity, the
variation of physical and mental components of the quality
of life () was calculated, and the Kruskal–Wallis test was
used to compare groups under drug treatment (control × anti-
inﬂammatory × chondroitin/glucosamine).
Results
Ninety-one elderly patients with OA, predominantly female
(71.4% of the sample), participated in the study. The age
of the individuals was 70.4 ± 5.6 years, and it was observed
that the study population presented high BMI  (29 ± 5.2). The
descriptive data of the study population are presented in
Table 1. Table 2 lists the results of the groups in the ﬁrst
and second evaluations, with a statistically signiﬁcant decline
of the physical and mental components of quality of life
(p < 0.05, Table 2) in all groups, according to the Wilcoxon
test. It was observed that users of chondroitin/glucosamine
had a smaller decline in the physical component of qualitytest (p = 0.007, Table 2, Fig. 1A). On the other hand, the inﬂuence
of the pharmacological treatment on the mental compo-
nent of quality of life (p > 0.05, Table 2, Fig. 1B) was not
observed.
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Fig. 1 – Variation of physical ( Physical Comp., A) and mental ( Mental Comp., B) components of quality of life in relation
to pharmacological treatment.
Table 1 – Characterization of the variables of the study
population.
Variables Average Standard
Deviation
Age 70.36  5.57
BMI 28.99 5.25
Gender Absolute
frequency (n)
Relative
frequency (%)
Male 26 28.6
Female 65 71.4
Total 91 100.0
Pharmacological treatment Absolute
frequency (n)
Relative
frequency (%)
Control 50 54.9
Anti-inﬂammatory drugs 27 29.7
Chondroitin/Glucosamine 14 15.4
BMI, body mass index.
Table 2 – Comparison of groups in of the 1st and 2nd evaluatio
components of quality of life.
Groups Life quality
1st evaluation
Physical components
Control 77.500 
Anti-inﬂammatory drugs 78.667 
Chondroitin/glucosamine 80.417 
Mental components
Control 87.625 
Anti-inﬂammatory drugs 82.275 
Chondroitin/glucosamine 82.875 Discussion
OA is the most common joint disease in the world,6 which jus-
tiﬁes the importance of the study of this disorder on quality of
life of senior patients. Moreover, OA is closely related to aging,
causing pain and functional disability, with major social, psy-
chological and economic losses, triggering the worsening of
quality of life of these individuals.5
As the individual ages, the disease tends to progress as a
result of the biomechanical aspects, causing deﬁcit in func-
tionality and quality of life,10 since there is a process inversely
proportional between disease progression and the quality of
life of patients,12 as demonstrated in the results of this study.
The BMI average was 28.99, corroborating other studies that
show an association between OA and overweight, since obe-
sity is the most signiﬁcant factor for the onset of the disease.13
In addition to that, obesity is associated with lower social
classes.14
This sample was composed mostly by women and, accord-
ing to evidence observed in other studies, women tend to have
greater joint involvement as the quality of life declines,10 facil-
itating the explanation of the negative variation perceived
in all groups. This result could be explained by greater joint
ns and with regard to variation of physical and mental
Life  quality 2nd
evaluation
p
48.375 <0.001
48.000 <0.001
56.375 0.003
65.437 <0.001
55.662 0.037
59.662 0.01
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nvolvement, probably associated to clinical and functional
hanges.15 OA is much more  frequent among women above
he age of 55,16 especially among women from lower social
lasses.14
Thus, one can infer that poorer quality of life is associ-
ted with a worse functional capacity of patients with OA,17
ince the main problems of OA are pain and discomfort, which
n turn cause functional limitations and changes in social
ehavior.18
While several advances have been made in trying to elu-
idate the pathogenesis of the OA, focusing on joint damage
nd changes in the joint’s synovial ﬂuid,19 there is still no cure
or this disease,12 another factor that helps us understanding
he worsening of the quality of life of the patients observed in
his study.12
Although there is no cure, treatments can be divided into
onventional (drug and physiotherapy) and surgical, and the
hoice of treatment will depend largely on the severity of the
oint damage.12
The pharmacological treatment aims to relieve the signs
nd symptoms of the disease and whenever it is possible,
educe its progression. Thus, the goals of this treatment are
ain relief, improving the quality of life, increasing mobility,
ncreasing the ability to walk and reducing the progression of
he disease.12
It was observed that the group treated with the chon-
roitin/glucosamine association showed a statistically less
igniﬁcant variation, leading to the assumption that this class
ould have better clinical efﬁcacy. The glucosamine sulfate
ssociated with chondroitin hydrochloride belongs to the
roup of OA-modifying drugs. It is known that the drug blocks
 potential change of the viscoelastic properties of the carti-
aginous tissue.12
The variation observed in the group treated with anti-
nﬂammatory drugs did not show a statistically signiﬁcant
ifference, probably due to mode of action of this drug type
hat act on the general treatment of symptoms (pain, fever and
nﬂammation). However, there is still controversy over their
ffectiveness in pain from musculoskeletal conditions, with
igniﬁcant variation in the response of these drugs according
o each individual.20 According to several random clinical tri-
ls, NSAIDs produced better results with regard to pain when
ompared to placebo, but with worse results when compared
o patients treated with painkillers.21
NSAIDs operate by inhibiting the synthesis of
rostaglandins, which is known as a primary anti-
nﬂammatory mechanism; prostaglandins are inﬂammatory
ediators that contribute to pain and inﬂammation in a
rocess mediated by cyclooxygenase enzymes (COX-1 and
OX-2),19 i.e., they inhibit COX-1 and COX-2. Despite the
iomechanical characteristics of the disease, its pathophysi-
logy is caused by an imbalance between the mechanisms
f formation and degeneration of the cartilage matrix, being
his process regulated by proinﬂammatory cytokines, such
s the interleukin-1 (IL-1), the tumor necrosis factor alpha
TNF-alpha) and proteinases. Despite being widely used, the
fﬁciency and safety of NSAIDs as a method of treatment of
A have not yet been elucidated.12 The size of the sample and
he lack of evaluation of drugs effects in the sense of being or
ot being dose-dependent were limiting factors for this study.
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Therefore, we suggest subsequent population-based studies
to conﬁrm these results.
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